ETF Holdings Breakdown of ANIP

ANIP institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-09-26	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	15,340	USD 1,427,387
2025-09-26	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	1,023	USD 95,190
2025-09-26	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	12,300	USD 1,144,515
2025-09-26	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	12,300	USD 1,144,515
Total =		40,963	USD 3,811,607

Book value of shares is calculated on the adjusted close price of each day (row).

News associated with ANIP

HC Wainwright Forecasts Strong Price Appreciation for ANI Pharmaceuticals (NASDAQ:ANIP) Stock

ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) had its target price increased by HC Wainwright from $93.00 to $121.00 in a report issued on Wednesday, MarketBeat Ratings reports. The firm currently has a “buy” rating on the specialty pharmaceutical company’s stock. HC Wainwright’s price objective would suggest a potential upside of 24.13% from the stock’s […] - 2025-09-19 03:05:01

ANI Pharmaceuticals (NASDAQ:ANIP) Reaches New 12-Month High Following Analyst Upgrade

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) hit a new 52-week high on Tuesday after Guggenheim raised their price target on the stock from $86.00 to $114.00. Guggenheim currently has a buy rating on the stock. ANI Pharmaceuticals traded as high as $96.66 and last traded at $96.30, with a volume of 66131 shares […] - 2025-09-10 02:20:55

ANI Pharmaceuticals (NASDAQ:ANIP) COO Sells $4,618,078.50 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) COO Muthusamy Shanmugam sold 52,990 shares of the firm’s stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $87.15, for a total transaction of $4,618,078.50. Following the completion of the sale, the chief operating officer directly owned 531,920 shares […] - 2025-08-21 05:19:08

Deutsche Bank AG Trims Stock Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Deutsche Bank AG trimmed its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 6.1% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 218,086 shares of the specialty pharmaceutical company’s stock after selling 14,242 shares during […] - 2025-08-15 05:15:08

ANI Pharmaceuticals (NASDAQ:ANIP) Stock Price Expected to Rise, Truist Financial Analyst Says

ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) had its target price raised by investment analysts at Truist Financial from $65.00 to $77.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage currently has a “hold” rating on the specialty pharmaceutical company’s stock. Truist Financial’s target price suggests a potential downside of 12.84% […] - 2025-08-13 02:46:43

Victory Capital Management Inc. Has $1.13 Million Stock Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Victory Capital Management Inc. grew its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 22.4% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 16,863 shares of the specialty pharmaceutical company’s stock after buying an additional 3,086 shares during the period. Victory Capital […] - 2025-07-31 05:28:47

Bank of New York Mellon Corp Reduces Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Bank of New York Mellon Corp lessened its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 3.7% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 119,262 shares of the specialty pharmaceutical company’s stock after selling 4,570 shares during the quarter. Bank of New York Mellon Corp’s holdings in ANI Pharmaceuticals […] - 2025-07-23 04:30:44

Louisiana State Employees Retirement System Has $522,000 Stock Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Louisiana State Employees Retirement System cut its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 2.5% during the first quarter, Holdings Channel.com reports. The firm owned 7,800 shares of the specialty pharmaceutical company’s stock after selling 200 shares during the quarter. Louisiana State Employees Retirement System’s holdings in ANI Pharmaceuticals were worth $522,000 […] - 2025-07-21 05:16:50

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives $78.88 Consensus Target Price from Analysts

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) has been assigned an average recommendation of “Buy” from the nine ratings firms that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation, seven have given a buy recommendation and one has given a strong buy recommendation to the […] - 2025-07-18 02:23:01

GAMMA Investing LLC Has $95,000 Stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

GAMMA Investing LLC lifted its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 163.8% during the first quarter, Holdings Channel.com reports. The firm owned 1,419 shares of the specialty pharmaceutical company’s stock after purchasing an additional 881 shares during the period. GAMMA Investing LLC’s holdings in ANI Pharmaceuticals were worth $95,000 […] - 2025-07-07 04:17:14

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives $80.13 Average PT from Brokerages

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) has received an average recommendation of “Buy” from the nine brokerages that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation, seven have issued a buy recommendation and one has given a strong buy recommendation to the company. The […] - 2025-06-23 02:14:07

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives $80.13 Average Target Price from Analysts

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) has received a consensus recommendation of “Buy” from the nine analysts that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation, seven have assigned a buy recommendation and one has given a strong buy recommendation to the company. […] - 2025-05-29 02:27:28

Comerica Bank Has $1.04 Million Stock Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Comerica Bank lowered its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 30.1% in the 4th quarter, HoldingsChannel reports. The firm owned 18,830 shares of the specialty pharmaceutical company’s stock after selling 8,099 shares during the period. Comerica Bank’s holdings in ANI Pharmaceuticals were worth $1,041,000 at the end of the […] - 2025-05-13 05:42:52

MetLife Investment Management LLC Has $630,000 Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

MetLife Investment Management LLC increased its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 6.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 11,397 shares of the specialty pharmaceutical company’s stock after buying an additional 675 […] - 2025-05-05 06:01:03

Dimensional Fund Advisors LP Raises Stock Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Dimensional Fund Advisors LP raised its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 4.6% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 685,730 shares of the specialty pharmaceutical company’s stock after purchasing an additional 30,420 […] - 2025-05-05 05:20:53

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Consensus Recommendation of “Buy” from Analysts

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) has been given an average rating of “Buy” by the nine analysts that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, seven have issued a buy recommendation and one has given a strong buy recommendation to […] - 2025-05-01 02:12:50

Legal & General Group Plc Acquires 2,585 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Legal & General Group Plc increased its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 5.6% during the fourth quarter, Holdings Channel.com reports. The fund owned 48,425 shares of the specialty pharmaceutical company’s stock after purchasing an additional 2,585 shares during the quarter. Legal & General Group Plc’s holdings in ANI […] - 2025-04-24 05:18:54

Invesco Ltd. Lowers Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Invesco Ltd. lowered its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 10.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 197,545 shares of the specialty pharmaceutical company’s stock after selling 22,814 shares during the quarter. Invesco […] - 2025-04-23 05:08:58

ANI Pharmaceuticals (NASDAQ:ANIP) Stock Price Expected to Rise, Truist Financial Analyst Says

ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) had its target price upped by analysts at Truist Financial from $62.00 to $65.00 in a report released on Monday,Benzinga reports. The brokerage currently has a “hold” rating on the specialty pharmaceutical company’s stock. Truist Financial’s price target points to a potential downside of 5.73% from the company’s […] - 2025-04-23 02:42:48

Vanguard Group Inc. Sells 33,739 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Vanguard Group Inc. reduced its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 2.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,314,372 shares of the specialty pharmaceutical company’s stock after selling 33,739 shares during the quarter. Vanguard […] - 2025-04-11 04:52:47

ANI Pharmaceuticals (NASDAQ:ANIP) Stock Rating Lowered by StockNews.com

ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) was downgraded by StockNews.com from a “hold” rating to a “sell” rating in a research note issued to investors on Tuesday. Other equities analysts have also recently issued reports about the stock. Leerink Partnrs raised shares of ANI Pharmaceuticals to a “strong-buy” rating in a research note on […] - 2025-04-10 03:13:02

Brokerages Set ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) PT at $79.75

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) has received a consensus rating of “Buy” from the nine brokerages that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold recommendation, seven have given a buy recommendation and one has given a strong buy recommendation to the company. The […] - 2025-04-09 02:04:49

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Position Trimmed by Corebridge Financial Inc.

Corebridge Financial Inc. reduced its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 7.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 9,778 shares of the specialty pharmaceutical company’s stock after selling 762 shares during the quarter. Corebridge […] - 2025-04-08 04:27:01

Thrivent Financial for Lutherans Reduces Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Thrivent Financial for Lutherans trimmed its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 1.5% in the 4th quarter, HoldingsChannel reports. The firm owned 12,828 shares of the specialty pharmaceutical company’s stock after selling 200 shares during the quarter. Thrivent Financial for Lutherans’ holdings in ANI Pharmaceuticals were worth $709,000 as of its […] - 2025-04-03 04:16:46

ANI Pharmaceuticals (NASDAQ:ANIP) Now Covered by Analysts at Jefferies Financial Group

Jefferies Financial Group initiated coverage on shares of ANI Pharmaceuticals (NASDAQ:ANIP – Free Report) in a report released on Friday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $80.00 target price on the specialty pharmaceutical company’s stock. Several other analysts have also recently commented on ANIP. StockNews.com cut shares of ANI […] - 2025-03-17 04:26:54

JPMorgan Chase & Co. Begins Coverage on ANI Pharmaceuticals (NASDAQ:ANIP)

JPMorgan Chase & Co. started coverage on shares of ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) in a research report issued to clients and investors on Wednesday, MarketBeat.com reports. The brokerage set an “overweight” rating and a $85.00 price target on the specialty pharmaceutical company’s stock. JPMorgan Chase & Co.‘s price objective would suggest a […] - 2025-03-14 04:34:45

Illinois Municipal Retirement Fund Decreases Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Illinois Municipal Retirement Fund lowered its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 8.6% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 8,533 shares of the specialty pharmaceutical company’s stock after selling 799 shares during the quarter. Illinois Municipal Retirement Fund’s […] - 2025-03-05 08:46:59

ANI Pharmaceuticals (NASDAQ:ANIP) Cut to Sell at StockNews.com

StockNews.com downgraded shares of ANI Pharmaceuticals (NASDAQ:ANIP – Free Report) from a hold rating to a sell rating in a report released on Monday morning. ANIP has been the subject of several other research reports. Leerink Partners assumed coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, December 11th. They set an […] - 2025-03-04 04:50:49

Brokerages Set ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Price Target at $77.71

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) have been given an average rating of “Buy” by the eight research firms that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation, six have given a buy recommendation and one has assigned a strong buy […] - 2025-02-18 04:13:03

abrdn plc Takes $13.16 Million Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

abrdn plc bought a new stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 237,965 shares of the specialty pharmaceutical company’s stock, valued at approximately $13,155,000. abrdn plc owned about 1.13% of […] - 2025-02-08 06:54:48

Back to Listing

Disclaimer